Kuros Biosciences AG (SWX:KURN)
Switzerland
· Delayed Price · Currency is CHF 21.10
-0.82 (-3.74%)
Apr 29, 2026, 12:05 PM CET
Kuros Biosciences AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 146.06 | 85.16 | 39.86 | 19.45 | 15.15 | Upgrade
|
| Revenue Growth (YoY) | 71.51% | 113.65% | 104.92% | 28.35% | 231.96% | Upgrade
|
| Cost of Revenue | 18.61 | 9.49 | 6.05 | 3.91 | 4.11 | Upgrade
|
| Gross Profit | 127.45 | 75.67 | 33.81 | 15.54 | 11.04 | Upgrade
|
| Selling, General & Admin | 107.95 | 67.81 | 37.73 | 20.96 | 15.41 | Upgrade
|
| Research & Development | 10.67 | 7.87 | 2.41 | 5.62 | 5.47 | Upgrade
|
| Other Operating Expenses | -0.13 | -0.13 | -0.29 | -0.39 | -0.23 | Upgrade
|
| Operating Expenses | 118.5 | 75.55 | 39.85 | 26.19 | 20.66 | Upgrade
|
| Operating Income | 8.95 | 0.12 | -6.04 | -10.65 | -9.62 | Upgrade
|
| Interest Expense | -0.37 | -0.17 | -0.22 | - | -1.52 | Upgrade
|
| Interest & Investment Income | 0.1 | 0.18 | - | - | 0.65 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.56 | 1.32 | -2.73 | -0.86 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.11 | 0.52 | 2.77 | -1.89 | - | Upgrade
|
| EBT Excluding Unusual Items | 5.02 | 1.98 | -6.22 | -13.4 | -10.48 | Upgrade
|
| Impairment of Goodwill | - | -5.75 | -5.19 | -3.89 | - | Upgrade
|
| Asset Writedown | - | - | -0.2 | - | - | Upgrade
|
| Pretax Income | 5.02 | -3.77 | -11.61 | -17.29 | -10.48 | Upgrade
|
| Income Tax Expense | 2.55 | 0.42 | 0.45 | -1.51 | -2.21 | Upgrade
|
| Earnings From Continuing Operations | 2.46 | -4.19 | -12.06 | -15.78 | -8.27 | Upgrade
|
| Earnings From Discontinued Operations | 0.09 | -0.65 | -4.24 | - | - | Upgrade
|
| Net Income | 2.55 | -4.84 | -16.3 | -15.78 | -8.27 | Upgrade
|
| Net Income to Common | 2.55 | -4.84 | -16.3 | -15.78 | -8.27 | Upgrade
|
| Shares Outstanding (Basic) | 38 | 37 | 37 | 34 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 37 | 37 | 34 | 33 | Upgrade
|
| Shares Change (YoY) | 11.26% | 1.69% | 7.91% | 3.37% | 34.86% | Upgrade
|
| EPS (Basic) | 0.07 | -0.13 | -0.45 | -0.47 | -0.25 | Upgrade
|
| EPS (Diluted) | 0.06 | -0.13 | -0.45 | -0.47 | -0.25 | Upgrade
|
| Free Cash Flow | -2.89 | 2.31 | -10.88 | -8.37 | -6.32 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | 0.06 | -0.30 | -0.25 | -0.19 | Upgrade
|
| Gross Margin | 87.26% | 88.85% | 84.83% | 79.89% | 72.86% | Upgrade
|
| Operating Margin | 6.13% | 0.14% | -15.15% | -54.74% | -63.46% | Upgrade
|
| Profit Margin | 1.75% | -5.68% | -40.90% | -81.15% | -54.59% | Upgrade
|
| Free Cash Flow Margin | -1.98% | 2.71% | -27.29% | -43.05% | -41.72% | Upgrade
|
| EBITDA | 11.52 | 2.32 | -3.55 | -8.11 | -6.96 | Upgrade
|
| EBITDA Margin | 7.89% | 2.72% | -8.91% | -41.70% | -45.90% | Upgrade
|
| D&A For EBITDA | 2.57 | 2.2 | 2.49 | 2.54 | 2.66 | Upgrade
|
| EBIT | 8.95 | 0.12 | -6.04 | -10.65 | -9.62 | Upgrade
|
| EBIT Margin | 6.13% | 0.14% | -15.15% | -54.74% | -63.46% | Upgrade
|
| Effective Tax Rate | 50.91% | - | - | - | - | Upgrade
|
| Revenue as Reported | 146.06 | 85.16 | 39.86 | 19.45 | 15.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.